Global pharmaceutical serialisation mandates are largely driven by the need for a protected supply chain, meaning no counterfeit product enters the supply chain, and no legitimate product is diverted from its intended destination. Steve Tallant of Systech identifies other intended benefits, such as expedited recall facilitation, better supply chain visibility and enhanced product tracking, discussing private and public Blockchain-based networks.